NBIX vs QNCX · P/E 45, rev $1.77B vs $79.3M cap
Neurocrine Biosciences Inc (NBIX) versus Quince Therapeutics, Inc. (QNCX) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Quince Therapeutics, Inc. (QNCX) is a biotechnology company listed on US.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
QNCX does not have a complete income-statement cache yet.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. QNCX currently screens at market cap $79.3M.
Not investment advice. Open the NBIX and QNCX stock pages for the full models.
Not investment advice.